SCIENTIFIC ADVISORY BOARD OF FIRALIS
Firalis product development pipeline and proprietary research projects are regularly discussed, evaluated and revised for all scientific and technical issues, as well as Go/No-Go recommendations based on interim project results and internal scientific reports. To that purpose, Firalis has established a Scientific Advisory Board, consisting of experts with several decades of experience in fundamental research, biotechnology and R&D project management. Scientific Advisory Board is organized regularly with the following objectives:
- to prioritize projects with highest market potentials
- to revise and reallocate resources on products closer to market
- to guarantee wisest spending of company budget
- to organize and assure wisest allocation of available human resources
Members of Firalis' Scientific Advisory Board :
Prof. Olivier DANOS, Chairman
With a Master’s degree in Genetics and Molecular Biology (University of Paris Orsay), Ph.D. at the Pasteur Institute and University of Paris Didero, Olivier is a pioneer in the field of gene therapy with a career dedicated to advancing its use, to develop life-saving therapies. Presently the Senior VP and CSO of REGENXBIO, former Senior VP of Cell and Gene Therapy at Biogen. Over the past twenty years, he has played leadership roles in cell and gene therapy as Director of the Gene Therapy Consortium of the University College of London, at the Necker Hospital - Enfants Malades in Paris, as Chief Scientific Officer of Genethon and as Senior Director of Research at Somatix Therapy Corporation. Also, he has held senior research positions in France, at CNRS (Centre National de la Recherche Scientifique) and Pasteur Institute. He is the former President and a founding member of the European Society of Gene and Cell Therapy.
Prof. Olivier Danos is a founder associate, member of the Supervisory Board and the Chairman of the Scientific Advisory Board of FIRALIS SA.
Prof. Dr. Dan ATAR
Professor of Cardiology, graduate of Basel University, trained in internal medicine and cardiology in Switzerland, Denmark and the US. Post-doc at John Hopkins University in Baltimore (91-94) and the Universities of Copenhagen and Zurich, where he worked as a senior cardiologist. In 2002, he received full professorship in cardiology at the University of Oslo and was appointed Head of Cardiology Dept. at the Aker University Hospital in Oslo, and since 2010 the Oslo University Hospital.
Currently he's the Head of Research at Oslo University Hospital Ulleval, Dept. of Medicine, Professor in Cardiology and a Visiting Associate Professorship at the Johns Hopkins University in Baltimore, USA. He has written over 440 articles and book chapters (H-index 70) and holds the fellowship-titles FESC, FACC and inaugural FAHA. Former Chairman of the ESC Working Group on Cardiovascular Pharmacotherapy. He was chairing an EU-FP7 research consortium (Mitocare) to study reperfusion injury in STEMI. He was on a number of ESC guideline writing committees, amongst others the 2010, 2012 and 2016 ESC Guideline on Atrial Fibrillation as well as the 2012 STEMI-guideline and the 2018 Universal Definition of AMI Guideline. In 2012 he was elected as Councillor and Board member, in 2014 as VP and in 2018 as Treasurer of the ESC. Last two years, he served as Chairman of the Clinical Advisory Board at FIBREX Medical Inc., France.
For his scientific achievements, he earned a doctor honoris causa in 2015 and since 2016 he appears on the prestigious Thomson-Reuters list of “the most cited scientists of the world”.
Prof. Thomas F. LUSCHER MD, FRCP
Thomas LUSCHER is a Professor of Cardiology, London, UK. Formerly, Prof. LUSCHER has been the Chairman of the Cardiology Department of the University of Zurich, as well as theDirector of the Center for Molecular Cardiology also at the University of Zurich and currently Thomas LUSCHER is the Director of Research, Education & Development at Royal Brompton & Harefield Hospital Trust, Consultant of Cardiology at the Imperial College in London, also the Editor-in-Chief European of the Heart Journal.
Prof LUSCHER has approximatively 900 publications in cardiovascular research and among more than 20 awards, he has also received the “Mayo Clinic Distinguished Alumni Award” in 2012 and “Werner Forssmann Award” from Charité Hospital, Berlin.
Prof. Pierre-Simon ROHRLICH
MD in pediatry (1991), practiced as an associate professor in Pediatric hemato-immunology at Robert-Debré Hospital in Paris where he specialized in hematopoietic stem cell transplantation. In 1995, he obtained his diploma in Transfusion Medicine and Immunohematology (DESC). After his PhD of Immunology at Pasteur Institute in 2003, he worked on human CMV infections and on the role of HFE molecules in human physiopathology. His pioneer results on the immune aspects of HFE have been acknowledged worldwide. He has been accredited as research director, and appointed as Professor in Pediatric hematology (PU-PH) at University of Franche-Comté. He is a member of the French National Bio-vigilance committee, lecturer in several academia, a member of University management committee and promoter of several clinical programs in pediatric hematology and immunology. His current interests focus on biomarkers of individual response to immunomodulators.
Yvan DEVAUX, PhD
Group Leader at Public Health Research, Chair of EU-CardioRNA COST Action.
He has a background in Biological Sciences, focusing on Biology and Health during his PhD in France and a post-doc in the US. He joined the Luxembourg Institute of Health (LIH) in 2005 and became Head of the Cardiovascular Research Unit in 2017. His main interest is the discovery and validation of novel RNA biomarkers and therapeutic targets of cardiac disease. Since his research is translational and he believes that collaboration can forward this area of research, he founded the Cardiolinc network in 2014 to bring together complementary expertise from clinicians, basic researchers, statisticians, bioinformaticians, systems biologists and industrials; towards the satisfaction of unmet medical needs. He is Chair of the EU-CardioRNA COST Action which gathers 180+ researchers from 36 countries worldwide with the aim to catalyze the research on RNAs in cardiovascular disease.